Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024
October 28, 2024 09:00 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving...
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
September 16, 2024 09:00 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
September 05, 2024 09:00 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals, a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients...
Shuttle Pharma Provides Second Quarter 2024 Corporate Update
September 04, 2024 16:15 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
August 28, 2024 09:00 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty...
Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)
August 26, 2024 16:10 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty...
Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
August 14, 2024 16:10 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
July 19, 2024 09:00 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., July 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer
June 18, 2024 09:00 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
May 22, 2024 16:15 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., May 22, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the...